# Yes, absolutely," GSK's Hesham Abdullah said on the call.

*biotech · news · 2026-04-12 · Reuters*

## Key points

- GSK's Mo-rez showed a 62% tumor shrinkage rate in platinum-resistant ovarian cancer patients.
- Mo-rez achieved a 67% tumor shrinkage rate in endometrial cancer patients in early trials.
- GSK plans to initiate three additional Mo-rez studies in the coming months.
- Mo-rez targets the B7H4 protein, which is present on gynecological cancer cells but rare in healthy tissue.
- The antibody-drug conjugate market is projected to reach $31 billion by 2030.

**Companies:** GSK
**Countries:** Puerto Rico

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-sees-blockbuster-potential-targeted-cancer-therapy-after-promising-early-2026-04-12/)

---

Canonical: https://newsio.io/n/dc51e573-bf0f-4f11-ac06-24031a87f766/yes-absolutely-gsks-hesham-abdullah-said-on-the-call
Summarized by Newsio from Reuters. https://newsio.io/how-it-works